Recent Updates
Recently added Catalysts

Solbinsiran

Phase 2

Severe Hypertriglyceridemia | Small molecule | Other |Eli Lilly and Company|Last Updated: Apr 22, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment60
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07269210A Study of Solbinsiran (LY3561774) in Participants With Severe HypertriglyceridemiaPHASE2 RECRUITING 60 — — Dec 8, 2025Aug 1, 2027Apr 22, 202640 United States, Canada +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change from Baseline in Triglycerides
Baseline, Weeks 16-24 (Time-Average)
Secondary Endpoints
Change from Baseline in Angiopoietin-like-3 (ANGPTL3)
Baseline, Week 24
Change from Baseline in Very-Low-Density Lipoprotein-Cholesterol (VLDL-C)
Baseline, Week 24
Change from Baseline in Non-High-Density Lipoprotein-Cholesterol (non-HDL-C)
Baseline, Week 24
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
SolbinsiranEXPERIMENTALParticipants will receive solbinsiran subcutaneously (SC)
PlaceboPLACEBO_COMPARATORParticipants will receive placebo SC
Interventions
NameTypeDescription
SolbinsiranDRUGAdministered SC
PlaceboDRUGAdministered SC
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites40

Inclusion Criteria: * History of fasting triglyceride levels of ≥500 milligrams per deciliter (mg/dL), based on medical history * Fasting triglyceride level ≥500 mg/dL at two separate visits during screening (at least 7 days apart) * Have a body mass index (BMI) within the range of 18.5 to 45.0 kil...

Countries:United StatesCanadaChinaJapan
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07269210primaryCompletionDate: changed
LOWMay 24, 2026NCT07269210studyFirstPostDate: changed